STERIS plc (Ireland)NYSE: STE
Health Care · Health Care Equipment
$215.17
-0.79%
Vol: 479K
Research Digest
Friday, May 1, 2026
STERIS Q3 FY26 shows 9% revenue and EPS growth despite tariff headwinds, Q4 results May 12
STERIS announced fiscal Q3 2026 results with 9% revenue growth and organic growth of 8%, with 9% EPS growth. Adjusted EPS increased to $2.53. Board authorized new $500 million share repurchase program. Announced quarterly dividend of $0.47 per share. Q4 earnings expected May 12. Company maintaining fiscal 2026 guidance despite significant tariff headwinds and strong capital equipment backlogs.
Previous Market Intelligence
13 daysApr 30STERIS is set to report Q4 2026 earnings on May 11 with analysts projecting diluted EPS of $2.89 (5.5% YoY increase) amid $30M tariff costs and $40M legal settlement impacts.Mixed▶
STERIS faces Q4 earnings ahead on May 11 with analyst expectations for $2.89 EPS (5.5% YoY growth) and guidance of 6%-7% revenue growth and 7%-10% EPS growth for fiscal 2026 despite headwinds. The company reported strong Q3 results with $1.5B revenue and $2.53 EPS but faces margin pressures from tariffs costing $30M and $40M legal settlement. Board authorized new $500M share repurchase program supporting long-term shareholder value. Analyst average rating is Buy with $275.2 price target (25.23% upside), though concerns exist about low return on invested capital versus peer performance.
Apr 29STERIS reports Q3 FY2026 organic revenue growth of 8% and 9% EPS growth; maintains full-year guidance despite tariff headwindsPositive▶
STERIS announced strong Q3 FY2026 results with total revenue from continuing operations up 9% on reported basis, with 8% constant currency organic growth. As reported EPS from continuing operations increased to $1.96, with adjusted EPS up to $2.53. AST segment revenue increased 11% with 9% service revenue growth and 103% capital equipment revenue growth. Life Sciences revenue increased 7% with 11% consumable growth. Guidance was tightened due to currency headwinds, but free cash flow and order growth remain strong. Company announced quarterly dividend of $0.63 per share on January 28, 2026. Average 12-month analyst target is $275.2 with 5 analysts rating Buy, implying 25.23% upside.
Apr 16Steris Q3 FY2026 adjusted EPS of $2.53 matched consensus; stock down 11.34% in past month but 5 analysts rate Buy.Mixed▶
STERIS plc reported Q3 FY2026 results on February 4, 2026 with total revenue from continuing operations up 9%, constant currency organic revenue growth of 8%, and adjusted EPS of $2.53 matching consensus. Applied Sterilization Technologies revenue increased 11% with 103% growth in capital equipment. Life Sciences segment revenue increased 7% with 11% consumable growth. The company declared quarterly dividend of $0.63 per share. Piper Sandler maintains Buy rating. Five analysts rate stock Buy with 12-month target of $275.20, indicating 23.64% upside from $222.58. Stock down 11.34% over past month despite ongoing revenue growth.
Apr 15STERIS extends former CFO advisory role; stock passes quality investing screen amid healthcare momentum.Neutral▶
STERIS extended former CFO Michael J. Tokich's advisory role through March 31, 2027. Piper Sandler maintained Buy rating. For fiscal 2026 Q3, STERIS reported adjusted EPS of $2.53 matching consensus. FY 2026 adjusted EPS guidance of $10.15-$10.30. Oak Thistle LLC boosted its position by 279.2% during Q4 2025.
Apr 14STERIS extended former CFO advisory role through March 2027; stock down slightly at $218.71 with moderate buy and $279 target.Neutral▶
STERIS extended former CFO Michael Tokich advisory role through March 31, 2027. Q3 2026 earnings were $2.53 per share. Stock trades near $218 with 8 analysts covering at average $279.29 target (27% upside). Next earnings May 20, 2026.
Apr 13STERIS reports FY25 revenue growth of 6.24% but faces margin pressures from tariffs and inflation; Q3 EPS $2.53.Neutral▶
STERIS reported FY 2025 revenue of $5.46B (up 6.24% YoY) with earnings of $614.64M (up 62.50%). Q3 delivered $1.5B revenue and $2.53 EPS but faced margin pressure from tariffs. Analyst consensus: Buy with 5 analysts covering; PT $275.20 (+23.64% upside). Quarterly dividend: $0.63 per share.
Apr 10STERIS FY2026 Q3 results show 9% revenue growth; Buy affirmedPositive▶
Revenue up 9%, adjusted EPS $2.53. Applied Sterilization Technologies grew 11%. Analyst consensus Buy with $275 target.
Apr 9STERIS reports Q3 fiscal 2026 revenue growth of 9% with stable FY guidanceNeutral▶
STERIS announced Q3 fiscal 2026 continuing-operations revenue of $1.5B (+9% YoY) with constant currency organic growth of 8%. Applied Sterilization Technologies grew 11% YoY to $286.6M with 103% capital equipment revenue growth. STERIS maintained FY 2026 adjusted EPS guidance of $10.15-$10.30 and 8-9% revenue growth. Tariffs expected to reduce pre-tax profit by ~$55M for FY 2026. Dividend of $0.63 per share announced, and institutional investor Oak Thistle increased stake by 279.2%.
Apr 8STERIS reports Q3 adjusted EPS of $2.53 matching consensus; faces margin pressures from tariffs.Neutral▶
STE Q3 adj EPS $2.53 matched consensus on $1.5B revenue. FY26 guidance $10.15-$10.30. Piper Sandler kept Buy March 17. Stock $258.43.
Apr 7STERIS Q3 FY26 Results: Revenue Up 9%, Adjusted EPS Meets GuidanceNeutral▶
STERIS reported fiscal Q3 2026 results on February 4, 2026 with total revenue from continuing operations increasing 9% and constant currency organic growth of 8%. Adjusted EPS reached $2.53 meeting consensus estimates. Applied Sterilization Technologies and Life Sciences segments showed strong performance.
Apr 6STERIS reports strong Q3 with $1.5B revenue but faces margin pressures from tariffs and inflation.Positive▶
STERIS reported strong Q3 results with revenue of $1.5 billion and EPS of $2.53, but the company faces margin pressures from tariffs and inflation. Analysts maintain a "Buy" rating with an average 12-month stock price target of $275.2, representing a 25.83% increase from current price. Piper Sandler kept its Buy rating on March 17, 2026. The company continues to benefit from growth opportunities in international markets. STERIS announced a quarterly interim dividend of $0.63 per share.
Apr 3No significant overnight updatesNeutral▶
No material news in the last 48 hours. STERIS next earnings expected May 20, 2026.
Apr 2STERIS maintains FY26 EPS guidance at $10.15-$10.30 after Q3 beat; CFO transition underwayPositive▶
STERIS plc announced Q3 FY2026 results on February 4, 2026 with total revenue from continuing operations increasing 9% and constant currency organic revenue growth at 8%. Reported Q3 EPS from continuing operations increased to $1.96 with adjusted EPS of $2.53. The Applied Sterilization Technologies (AST) segment showed 9% growth in service revenue and 103% growth in capital equipment revenue. Long-time CFO Michael J. Tokich is being succeeded by Karen L. Burton. The company announced a quarterly dividend of $0.63 per share on January 28, 2026.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| STESTERIS | $215.17 | -0.79% | -1.4% | 19.6x | 1.07 | $21.3B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.